舒尼替尼

舒尼替尼（CAS 557795-19-4）的公开数据库记录，列此仅供独立核对。

危险化学品分类与危害说明

物理形态与操作说明

• Solid
• Orange solid
• >25 mg/mL over pH of 1.2 to 6.8
• 溶解度 at 22 °C (ug/mL): 2582 in 20 mM KCl/HCl buffer (pH 2); 364 in 20 mM phosphate buffer (pH 6)
• 214.3 Ų [M+Na]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID4046492]
• 207.0 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID4046492]

公开数据库收录的理化数据

这个物质在各数据库里的编号

数据库记载的用途

• Use (kg; approx.) in Germany (2009): >25
• Consumption (g per capita; approx.) in Germany (2009): 0.000305
• The formation of the pyrrole was performed according to the classical Knorr synthesis, and hydrolysis of the tert-butylester with a subsequent decarboxylation reaction occurred smoothly with sulfuric acid in aqueous methanol at 65 °C. Thereafter, reaction with the Vilsmeier reagent (chloromethylenedimethylammonium chloride) in acetonitrile afforded the corresponding complex, which upon addition of 5-fluorooxindole and pulverized potassium hydroxide yielded the desired product.
• Sunitinib is multi-specific tyrosine kinase receptor inhibitor that is used in the therapy of gastrointestinal stromal tumors and advanced renal cell carcinoma. Sunitinib therapy is associated with transient elevations in serum aminotransferase and bilirubin levels and rare instances of clinically apparent acute liver injury.
• Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors;
• Angiogenesis Inhibitors; Antineoplastic Agents

它在各数据库里的别名

Sunitinib; 557795-19-4; SU11248; sunitinibum; SU-11248; Su-011248; NSC-750690; SU011248; NSC-736511; V99T50803M; DTXSID1041134; CHEBI:38940; RefChem:56080; DTXCID9021134; L01XE04; 111-194-2

计算机算出的分子描述符

数据库摘要

Sunitinib · CAS 557795-19-4 · C22H27FN4O2. UNII V99T50803M. 溶解度: 3.08e-02 g/L; LogP: 5.2; LogP: log Kow = 3.1.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。